The FDA recently approved a new drug called lorcaserin (brand name Belviq) for the treatment of obesity. Lorcaserin causes an average of 13 lbs (5.8 kg) of weight loss over a year, compared to 5 lbs (2.2 kg) for placebo (1), which is less than the other recently approved drug Qsymia (formerly Qnexa; topiramate/phentermine).
Learning about obesity drugs is always a good opportunity to gain insight into the mechanisms that underlie the development and reversal of obesity. If you've been following this blog for a while, you already have a pretty good guess what organ this new drug acts on. Make your guess and read on!
Read more »